Anti-Human MIF Recombinant Antibody (TAB-H41) (CAT#: TAB-H41)

Figure 1 Anti-Human MIF Recombinant Antibody (TAB-H41) in SDS-PAGE

SDS-PAGE analysis of TAB-H41 in β-mercaptoethanol-reduced (Lane 1, 1.5 μg) and non-reduced (Lane 2, 1.5 μg) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.

Figure 2 Anti-Human MIF Recombinant Antibody (TAB-H41) in SEC-HPLC

The purity of TAB-H41 was greater than 98% as determined by SEC-HPLC.

Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl

Figure 3 Anti-Human MIF Recombinant Antibody (TAB-H41) in DB

Dot Blot analysis of TAB-H41 was performed by coating with human MIF protein (His tag).

TAB-H41-hIgG1 incubation concentration: 2 μg/mL.
HRP conjugated Anti-Human IgG Fc as a secondary antibody (1: 2000)

Figure 4 Anti-Human MIF Recombinant Antibody (TAB-H41) in ELISA

ELISA analysis of TAB-H41 was performed by coating with human MIF protein (His tag). Then blocked with BSA and incubated with TAB-H41-hIgG1. The HRP conjugated Anti-human IgG Fc as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 5 Anti-Human MIF Recombinant Antibody (TAB-H41) in WB

WB analysis of TAB-H41 was performed by coating with human MIF protein (His tag).
TAB-H41 incubation concentration: 1 μg/mL.
HRP conjugated Anti-Human IgG Fc as a secondary antibody (1: 2000)
Lane 1: Reduced Antigen (0.1 μg)
Lane 2: Reduced Antigen (0.3 μg)
Lane 3: Reduced Antigen (0.6 μg)